GlaxoSmithKline's Advair Reduces Exacerbations in COPD Patients
Posted on: Monday, 19 May 2008, 12:00 CDT
GlaxoSmithKline has reported that the use of its Advair Diskus 250/50 demonstrated a 30% reduction in exacerbations in patients with chronic obstructive pulmonary disease who have a history of exacerbations as compared with salmeterol alone.
The randomized study of 797 patients was a replicate study which found that after a year of treatment, patients treated with Advair Diskus 250/50 had a 30% reduction in the rate of annual exacerbations compared to salmeterol (p<0.001).
In an analysis of time to first moderate/severe exacerbation, there was a 25% reduction in risk with Advair compared to salmeterol (p=0.003). And Advair also reduced the annual rate of exacerbations requiring oral corticosteroids by 40% (p<0.001).
Antonio Anzueto, managing director of University of Texas Health Science Center, said: "Reducing exacerbations is one of the primary goals of chronic obstructive pulmonary disease (COPD) treatment, and this second study presented shows convincingly that Advair effectively addresses this pressing need. This data reaffirms my belief in Advair as an effective treatment for my patients with chronic obstructive pulmonary disease (COPD)."
Source: Datamonitor
Related Articles
- Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations
- New Analyses from 16-Year Follow-up Trial with Betaseron(R) Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes
- BRIGHT Results Show Less Pain and Higher Patient Satisfaction With Betaseron(R) Than With Rebif(R)
- Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
- Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
- First of Its Kind Data Show: Immediate Treatment of Early MS Patients With Betaseron(R) Significantly Delayed Permanent Disability
- The Effects of Cocaine and Heroin Use on Intubation Rates and Hospital Utilization in Patients With Acute Asthma Exacerbations*
- Bacteria and Airway Inflammation in Chronic Obstructive Pulmonary Disease: More Evidence
- Exacerbations and Time Spent Outdoors in Chronic Obstructive Pulmonary Disease
- Managing Patients With Recurrent Acute Exacerbations of Chronic Bronchitis: a Common Clinical Problem
 |
 |
User Comments (0)
RSS Feeds